|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
Response over the company's new Alzheimer drug endpoint has been both critical and supportive.
Also, data on personal income and spending, the Chicago PMI and the University of Michigan's revised consumer sentiment survey are all on the schedule.
The drugmakers are using a new and unproven endpoint for their closely watched bapineuzumab drug.
The biotech company delivers better-than-expected fourth-quarter and year-end earnings and sales.
Fans and foes of the company's Alzheimer's drug stick to their guns.
The drug, a 50/50 venture between Biogen and Elan, is cleared to treat the rare disease.
Here's an overview of the outlooks offered at last week's JPMorgan confab and a look at what's to come.
The biotech sector hinges on presidential race, FDA and mergers.
Myriad Genetics and Dendreon are among those with major clinical trials next year.
Cramer says to pull the trigger while the oil service stock is cheap.
A decision on the drug's use as a Crohn's disease treatment is likely by Jan. 13.
A sneak peak at which names in the sector will be reporting results in the coming two weeks.
It has already received some expressions of interest, including one from Carl Icahn.
The payoff may come later, but these focused companies should still get a look.
It would provide a clear signal of the negative divergences going into next week.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.